What is Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF)?

Category: Prescription Drugs

Most popular types: Biktarvy

false

Bictegravir-emtricitabine-tenofovir alafenamide is a combination drug used to treat HIV-1 in adults.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 1
Mild 2
None 1

Commonly reported side effects and conditions associated with Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF)

Side effect Patients Percentage
Headaches 2
Nausea 1
Weight gain 1

Dosages

Based on patients currently taking Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF)

Dosage Patients Percentage
50-200-25 mg daily 4

Duration

Currently taking Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF)

Duration Patients Percentage
1 - 6 months 2
6 months - 1 year 2
Adherence
Adherence Evaluations Percentage
Always 4
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 3
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 1
< $25 1
Not specified 2

What people switch to and from

Patients started taking Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) after stopping:

Treatment Patients Percentage
Darunavir-cobicistat (DRV/c) (Prezcobix) 1
Efavirenz-Emtricitabine-Tenofovir disoproxil fumarate (Atripla) 1
Last updated:
There are no evaluations for Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF).